|Awarded On||November 16, 2016|
|Title||Targeting the Inflammatory Cancer Stem Cell Microenvironment of Triple Negative Breast Cancer with Leukocyte-mimetic Nanovesicles|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The Methodist Hospital Research Institute|
|Principal Investigator/Program Director||Ennio Tasciotti|
Triple negative breast cancer (TNBC) tumors, which lack the expression of progesterone receptor, estrogen receptor, and human epidermal growth factor receptor 2, account for 10-20% of all breast cancer patients. Currently, no targeted therapy exists for TNBC, linking this disease with poor prognosis and an increased risk of relapse and metastatic progression. A sub-population of cancer cells with stem cell-like features is believed to be responsible for this resistance to therapy and metastatic progression. The growth and self-renewal features of these cells are fueled by inflammation and key signaling pathways. Our proposed technology aims to revolutionize TNBC treatment by developing ther...